Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis.

What Was Tested

Researchers studied Vitamin D and Calcium in the context of osteoporosis and bone density in this randomized controlled trial publication.

The researchers also tested the possibility of using quantitative ultrasound (QUS) for assessing bone involvement in thalassemic osteopenia and in monitoring the response to antiresorptive therapy.

Who Took Part

The abstract describes 30 patients taking part.

The age groups tagged for this paper are adults, men only.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Because people in this Vitamin D study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A placebo (an inactive look-alike) gave the Vitamin D group a baseline to be compared against.

What Was Measured

The researchers also tested the possibility of using quantitative ultrasound (QUS) for assessing bone involvement in thalassemic osteopenia and in monitoring the response to antiresorptive therapy.

PubMed files the paper under topics including Amino Acids, Bone and Bones, Calcium, Clodronic Acid, Creatine, Osteoporosis and Ultrasonography.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D and Calcium in 30 patients in people with osteoporosis and bone density.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2003 (Journal of bone and mineral metabolism), a journal based in Japan.

More context: the related Vitamin D, K2, Magnesium and Zinc library page, Osteoporosis and bone density research.